CA3124267A1 - New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof - Google Patents
New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof Download PDFInfo
- Publication number
- CA3124267A1 CA3124267A1 CA3124267A CA3124267A CA3124267A1 CA 3124267 A1 CA3124267 A1 CA 3124267A1 CA 3124267 A CA3124267 A CA 3124267A CA 3124267 A CA3124267 A CA 3124267A CA 3124267 A1 CA3124267 A1 CA 3124267A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- group
- stat3
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783741P | 2018-12-21 | 2018-12-21 | |
| US62/783,741 | 2018-12-21 | ||
| PCT/CA2019/051884 WO2020124262A1 (en) | 2018-12-21 | 2019-12-20 | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3124267A1 true CA3124267A1 (en) | 2020-06-25 |
Family
ID=71100034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3124267A Pending CA3124267A1 (en) | 2018-12-21 | 2019-12-20 | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220089531A1 (https=) |
| EP (1) | EP3898582A4 (https=) |
| JP (1) | JP2022515248A (https=) |
| CN (1) | CN113661158A (https=) |
| CA (1) | CA3124267A1 (https=) |
| WO (1) | WO2020124262A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3174623A1 (en) * | 2020-03-05 | 2021-09-10 | Janpix, Ltd. | Stat inhibitory compounds and compositions |
| EP4114371A4 (en) * | 2020-03-05 | 2024-04-17 | Centessa Pharmaceuticals (UK) Limited | ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF |
| TW202227398A (zh) * | 2020-09-04 | 2022-07-16 | 英商詹皮克斯有限公司 | Stat抑制性化合物及組合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007136858A2 (en) * | 2006-05-19 | 2007-11-29 | H. Lee Moffitt Cancer Center & Research Institute | Small molecule inhibitors of stat3 with anti-tumor activity |
| CN103608010A (zh) * | 2010-08-02 | 2014-02-26 | 中央佛罗里达大学研究基金公司 | 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物 |
| CN102219755B (zh) * | 2011-05-05 | 2013-04-03 | 南京大学 | Stat3的小分子选择性抑制剂及其制备方法和应用 |
| CN110003104A (zh) * | 2012-05-25 | 2019-07-12 | 多伦多大学管理委员会 | 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
| WO2014070859A1 (en) * | 2012-10-30 | 2014-05-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Stat3 dimerization inhibitors |
| BR112016028022B1 (pt) * | 2014-05-30 | 2023-03-28 | The Governing Council Of The University Of Toronto | Compostos de sulfonamida inibidores de stat5 |
-
2019
- 2019-12-20 EP EP19901001.8A patent/EP3898582A4/en not_active Withdrawn
- 2019-12-20 WO PCT/CA2019/051884 patent/WO2020124262A1/en not_active Ceased
- 2019-12-20 JP JP2021536402A patent/JP2022515248A/ja active Pending
- 2019-12-20 CA CA3124267A patent/CA3124267A1/en active Pending
- 2019-12-20 CN CN201980089744.6A patent/CN113661158A/zh active Pending
- 2019-12-20 US US17/416,175 patent/US20220089531A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220089531A1 (en) | 2022-03-24 |
| EP3898582A4 (en) | 2022-08-24 |
| JP2022515248A (ja) | 2022-02-17 |
| WO2020124262A1 (en) | 2020-06-25 |
| CN113661158A (zh) | 2021-11-16 |
| EP3898582A1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101717098B1 (ko) | 디글리시드 에테르 유도체 치료법 및 이의 사용 방법 | |
| JP6543366B2 (ja) | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 | |
| JP6100439B2 (ja) | アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法 | |
| RU2639145C2 (ru) | Производные оксотиоимидазолидина, способы их получения и их применение в медицине в качестве ингибиторов андрогенного рецептора | |
| RU2727705C1 (ru) | Производное бензопиперидина, способ его получения и его медицинское применение | |
| JP2013537535A (ja) | Statタンパク質の阻害剤としての、置換2−ヒドロキシ−4−(2−(フェニルスルホンアミド)アセトアミド)安息香酸類似体 | |
| CA3124267A1 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| JP2021185193A (ja) | インデニル化合物、医薬組成物、およびその医学的使用 | |
| JP2015533778A (ja) | がんの治療のための新規フェニル−ピリジン/ピラジンアミド | |
| WO2018154118A2 (en) | Novel aromatic compounds | |
| CN114149424A (zh) | 用于治疗疾病的杂环化合物 | |
| WO2022249120A1 (ko) | 신규한 벤조인돌론 화합물 및 이를 포함하는 약학적 조성물 | |
| JP2023103371A (ja) | 新規の芳香族化合物 | |
| HK40063807A (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| EP4470608A1 (en) | Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis | |
| HK40070316A (en) | Heterocyclic compounds for the treatment of disease | |
| HK40015967A (en) | Inhibitors of the n-terminal domain of the androgen receptor | |
| HK1260375A1 (en) | Heterocyclic compounds for the treatment of disease |